How Do Bimzelx and Skyrizi Work for Plaque Psoriasis?
Bimzelx (bimekizumab) targets both IL-17A and IL-17F cytokines, which drive inflammation in plaque psoriasis. Skyrizi (risankizumab) targets only IL-23, an upstream regulator of IL-17. This dual blockade in Bimzelx may explain faster skin clearance in trials, but both reduce plaques effectively over time.[1][2]
What Do Head-to-Head Trials Show?
No direct head-to-head trials compare Bimzelx and Skyrizi specifically for plaque psoriasis. Indirect comparisons from phase 3 data suggest Bimzelx achieves higher PASI 90 (90% improvement) rates at week 16: 85% for Bimzelx vs. 75% for Skyrizi. PASI 100 rates favor Bimzelx (58% vs. 45%). These differences narrow by week 52, with both near 90% PASI 90.[3][4]
How Quickly Do They Clear Skin?
Bimzelx clears plaques faster. In trials, 45% of Bimzelx patients hit PASI 90 by week 4, vs. 13% for Skyrizi. Skyrizi ramps up more gradually, peaking later. Patients prioritizing rapid results often see Bimzelx as superior here.[1][2]
What About Long-Term Efficacy and Durability?
Over 52 weeks, both maintain high response rates (PASI 90: 91% Bimzelx, 87% Skyrizi). Bimzelx shows slightly better complete clearance (PASI 100: 62% vs. 56%). Real-world data is limited, but durability appears comparable, with low relapse after dosing.[3][4]
Side Effect Profiles: Which Is Safer?
Both have similar mild side effects like upper respiratory infections (15-20%). Bimzelx reports more oral candidiasis (10-15% vs. <5% for Skyrizi) due to IL-17 blockade. Skyrizi has fewer fungal issues but similar serious infection rates (1-2%). No major safety signals differentiate them long-term.[1][2]
Dosing, Cost, and Access Factors
Bimzelx: 320 mg every 4 weeks initially, then every 8 weeks. Skyrizi: 150 mg at weeks 0/4, then every 12 weeks. Bimzelx requires more frequent visits early on. U.S. list prices are close (~$6,000-7,000/month), but insurance coverage varies. Skyrizi has broader formulary access.[5]
Who Might Prefer Bimzelx Over Skyrizi?
Bimzelx suits patients needing fast clearance or failing IL-23 therapies. Skyrizi fits those wanting less frequent dosing or avoiding yeast infections. Guidelines (AAD/NPF) list both as first-line biologics; choice depends on speed vs. convenience.[6]
[1] Bimzelx (bimekizumab) prescribing information, UCB Pharma
[2] Skyrizi (risankizumab) prescribing information, AbbVie
[3] Gordon KB et al., Lancet 2021 (BE VIVID/READY trials for Bimzelx)
[4] Reich K et al., Lancet 2017 (IMMvent trials for Skyrizi)
[5] Drugs.com price comparison
[6] Armstrong AW et al., J Am Acad Dermatol 2021 (psoriasis guidelines)